In this study, we developed a robust, in vivo model of RUNX1-mutated CN-AML, a molecular subgroup of CN-AML that is relatively common, responds poorly to standard chemotherapy, and for which no molecularly targeted therapies exist. Here, RUNX1 is linked to acute myeloid leukemia.